日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Evaluation of the 1021-HRD assay compared to established HRD testing platforms in ovarian cancer

卵巢癌中1021-HRD检测方法与现有HRD检测平台的比较评估

Papadopoulou, Eirini; Fountzilas, Elena; Metaxa-Mariatou, Vasiliki; Tsantikidi, Aikaterini; Tsaousis, Georgios; Meintani, Angeliki; Florou-Chatzigiannidou, Chrysiida; Maxouri, Stella; Papazisis, Konstantinos; Floros, Theofanis; Papadimitriou, Christos; Timotheadou, Eleni; Papadopoulou, Kyriaki; Papathanasiou, Athanasios; Grigoriadis, Dimitrios; Fu, Xiaorui; Zheng, Xunmei; Xing, Yun; Du, Xinhua; Truican, Andreea; Nasioulas, George

Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice

在肿瘤临床实践中应用包含1021个基因的液体活检检测方法进行真实世界的肿瘤基因组分析

Florou-Chatzigiannidou, Chrysiida; Papadopoulou, Eirini; Metaxa-Mariatou, Vasiliki; Tsantikidi, Aikaterini; Maxouri, Stella; Tsaousis, Georgios; Grigoriadis, Dimitris; Touroutoglou, Nikolaos; Ziogas, Dimitrios; Zairi, Eleni; Alevizopoulos, Nektarios; Corneliu, Jinga Dan; Polixenia, Iorga; Ozdogan, Mustafa; Bilir, Cemil; Hacibekiroglu, Ilhan; Lacin, Sahin; Ajami, Ramin; El Hachem, Georges; Nasioulas, George; Bramis, Konstantinos; Konstadoulakis, Manousos; Papadimitriou, Christos

Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer

DUO-E 研究结果的简明语言总结:度伐利尤单抗联合或不联合奥拉帕尼治疗晚期子宫内膜癌患者

Westin, Shannon N; Moore, Kathleen; Chon, Hye Sook; Lee, Jung-Yun; Thomes Pepin, Jessica; Sundborg, Michael; Shai, Ayelet; de la Garza, Joseph; Nishio, Shin; Gold, Michael A; Wang, Ke; McIntyre, Kristi; Tillmanns, Todd D; Blank, Stephanie V; Liu, Ji-Hong; McCollum, Michael; Contreras Mejia, Fernando; Nishikawa, Tadaaki; Pennington, Kathryn; Novak, Zoltan; De Melou, Andreia Cristina; Sehouli, Jalid; Klasa-Mazurkiewicz, Dagmara; Papadimitriou, Christos; Gil-Martin, Marta; Brasiuniene, Birute; Donnelly, Conor; Liu, Xiaochun; Nieuwenhuysen, Els Van

Detection rate for ESR1 mutations is higher in circulating-tumor-cell-derived genomic DNA than in paired plasma cell-free DNA samples as revealed by ddPCR

ddPCR结果显示,循环肿瘤细胞来源的基因组DNA中ESR1突变的检出率高于配对的血浆游离DNA样本。

Smilkou, Stavroula; Ntzifa, Aliki; Tserpeli, Victoria; Balgkouranidou, Ioanna; Papatheodoridi, Alkistis; Razis, Evangelia; Linardou, Helena; Papadimitriou, Christos; Psyrri, Amanda; Zagouri, Flora; Kakolyris, Stylianos; Lianidou, Evi

Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer

评估聚(ADP-核糖)聚合酶抑制剂联合免疫疗法一线治疗晚期卵巢癌的3期临床试验

Rimel, B J; Pujade-Lauraine, Eric; Moore, Kathleen; Pfisterer, Jacobus; Han, Sileny; Cibula, David; Reyners, Anna; Redondo, Andrés; Papadimitriou, Christos; Eitan, Ram; Pignata, Sandro; Glasspool, Rosalind; Mirza, Mansoor Raza; Bodnar, Lubomir; Duska, Linda; Provencher, Diane; Phaëton, Rébécca; Bains, Manjinder; Coskuncay, Elif; Hardy-Bessard, Anne Claire

Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial

Durvalumab联合卡铂/紫杉醇治疗后序贯Durvalumab维持治疗(可联合或不联合奥拉帕尼)作为晚期子宫内膜癌的一线治疗:III期DUO-E试验

Westin, Shannon N; Moore, Kathleen; Chon, Hye Sook; Lee, Jung-Yun; Thomes Pepin, Jessica; Sundborg, Michael; Shai, Ayelet; de la Garza, Joseph; Nishio, Shin; Gold, Michael A; Wang, Ke; McIntyre, Kristi; Tillmanns, Todd D; Blank, Stephanie V; Liu, Ji-Hong; McCollum, Michael; Contreras Mejia, Fernando; Nishikawa, Tadaaki; Pennington, Kathryn; Novak, Zoltan; De Melo, Andreia Cristina; Sehouli, Jalid; Klasa-Mazurkiewicz, Dagmara; Papadimitriou, Christos; Gil-Martin, Marta; Brasiuniene, Birute; Donnelly, Conor; Del Rosario, Paula Michelle; Liu, Xiaochun; Van Nieuwenhuysen, Els

ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design

ENGOT-EN20/GOG-3083/XPORT-EC-042——一项III期、随机、安慰剂对照、双盲、多中心试验,评估塞利尼索在p53野生型、晚期或复发性子宫内膜癌患者系统治疗后维持治疗中的疗效:研究原理、方法和试验设计

Vergote, Ignace; Perez Fidalgo, Alejandro; Valabrega, Giorgio; Monk, Bradley J; Herzog, Thomas; Cibula, David; Colombo, Nicoletta; Pothuri, Bhavana; Sehouli, Jalid; Korach, Jacob; Barlin, Joyce; Papadimitriou, Christos A; van Gorp, Toon; Richardson, Debra; McCarthy, Michael; Antill, Yoland; Mirza, Mansoor Raza; Li, Kai; Kalyanapu, Pratheek; Slomovitz, Brian; Coleman, Robert L

Molecular Alterations in Paired Epithelial Ovarian Tumors in Patients Treated with Neoadjuvant Chemotherapy

接受新辅助化疗的患者配对上皮性卵巢肿瘤的分子改变

Nikolaidi, Adamantia; Papadopoulou, Eirini; Haidopoulos, Dimitrios; Liontos, Michalis; Fountzilas, Elena; Tsaousis, Georgios; Goula, Kalliroi; Tsolaki, Eleftheria; Christopoulou, Athina; Binas, Ioannis; Stamatopoulou, Sofia; Koumarianou, Anna; Karageorgopoulou, Sofia; Goussia, Anna; Psyrri, Amanda; Papadimitriou, Christos; Gogas, Helen

A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial

一项随机 III 期研究:比较 Arfolitixorin 与 Leucovorin 联合 5-氟尿嘧啶、奥沙利铂和贝伐珠单抗一线治疗转移性结直肠癌的疗效:AGENT 试验

Tabernero, Josep; Yoshino, Takayuki; Stintzing, Sebastian; de Gramont, Aimery; Gibbs, Peter; Jonker, Derek J; Nygren, Peter; Papadimitriou, Christos; Prager, Gerald W; Tell, Roger; Lenz, Heinz-Josef

Direct comparison of an ultrasensitive real-time PCR assay with droplet digital PCR for the detection of PIK3CA hotspot mutations in primary tumors, plasma cell-free DNA and paired CTC-derived gDNAs

直接比较超灵敏实时PCR检测与液滴数字PCR检测原发肿瘤、血浆游离DNA和配对CTC衍生gDNA中PIK3CA热点突变的能力

Smilkou, Stavroula; Kaklamanis, Loukas; Balgouranidou, Ioanna; Linardou, Helena; Papatheodoridi, Alkistis Maria; Zagouri, Flora; Razis, Evangelia; Kakolyris, Stylianos; Psyrri, Amanda; Papadimitriou, Christos; Markou, Athina; Lianidou, Evi